Alumis Inc.
ALMS
Classement en actions
#10425
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Prix de l'action
$6.15
Dernière synchronisation: 2026-10-16
Capitalisation boursière
$795.38M
Changement (1 jour)
-2.61%
Changement (1 an)
170.70%
Pays
US
Échange Alumis Inc. (ALMS)
Catégorie
Healthcare
Capitalisation boursière de Alumis Inc.(ALMS)
Capitalisation boursière: $795.38M
En October 2026, Alumis Inc. a une capitalisation boursière de $795.38M. Cela fait de Alumis Inc. la 10425th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Alumis Inc. du 2023 au 2026
ALMS par rapport au top 5 des plus populaires stocks
| Prix pour ALMS | L’actif B | La capitalisation boursière de B | Résultats | |
|---|---|---|---|---|
$52,771.39
$222.26M
|
$5.167T | +2,324,630.86% | ||
|
$51,216.34
$222.26M
|
$5.015T | +2,256,126.37% | ||
|
$41,959.44
$222.26M
|
$4.108T | +1,848,333.43% | ||
|
$39,850.45
$222.26M
|
$3.902T | +1,755,426.59% | ||
|
$27,467.63
$222.26M
|
$2.689T | +1,209,927.69% |
